IQVIA's Lowest Short Interest in a Year Sets a Clean Slate for Today's Print

Short interest in IQV has fallen to its lowest level in at least a year, now running at 1.8% of the free float after dropping a further 5.5% on October 26 alone and shedding 17% over the past month. The borrow market is correspondingly relaxed: cost to borrow has fallen sharply to 0.21%, down more than 60% over the past month, and availability is extremely loose at 6,788%, meaning shares to borrow vastly outnumber those already short. The options market is similarly calm, with a put/call ratio of 0.78, barely above its 20-day average and less than one standard deviation from normal. The stock closed at $271.55, down 0.7% on the day but up 1.4% on the week.

That weekly gain of 1.4% looks modest against the CRO and life sciences peer group, where the moves have been sharper. CRL rose 19% over the same five days, ICLR and MEDP both gained around 9%, and FTRE added 6.3%. IQV's relative underperformance into an active week for the sector is the context the print lands in: peers have repriced, and IQV has not moved with them.

The analyst community has nonetheless grown more constructive in the past month. Multiple firms raised price targets ahead of today, with Stifel moving to $303, Mizuho and Barclays each lifting to $300, and RBC making the sharpest revision, taking its target from $247 to $319. UBS reinstated at end of September with a Buy and a $345 target. The consensus mean now stands at $304.59, implying roughly 12% above the current price. Morgan Stanley remains the outlier, holding an Equal-Weight with a $270 target that sits below where the stock is trading today. The bull case centres on IQVIA's record near-term backlog of $9.2 billion, growing 7.5% year-on-year, and the boost expected from 20 novel drug approvals in Q3 2026, the highest quarterly count since 2021. Bears point to biotech funding uncertainty, biopharma consolidation, and above-average leverage as sources of earnings risk that the backlog alone cannot neutralise.

Insider activity has run one-way since the July print. Net sales over the past 90 days totalled approximately $29.9 million, with CEO Ari Bousbib accounting for the bulk of the selling in late July at prices in the $244 to $249 range. None of the recent trades were flagged as made under a 10b5-1 plan, which makes them discretionary rather than pre-arranged. At the institutional level, JP Morgan Asset Management and Franklin Templeton both added meaningfully in the most recent reported quarter, while the register is otherwise stable among the large passive holders.

Today's print will test whether IQV's bookings momentum and commercial-segment tailwinds can justify closing the gap with peers that have already moved, at a valuation where the stock trades at 19.3x earnings and with insiders having been net sellers through the recovery.